Design Therapeutics (NASDAQ:DSGN – Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, March 18th. Analysts expect Design Therapeutics to post earnings of ($0.27) per share for the quarter.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Design Therapeutics Stock Performance
Shares of NASDAQ:DSGN opened at $4.70 on Friday. The company’s 50-day moving average is $4.76 and its 200 day moving average is $5.35. The company has a market capitalization of $266.12 million, a P/E ratio of -5.53 and a beta of 1.77. Design Therapeutics has a fifty-two week low of $2.45 and a fifty-two week high of $7.77.
About Design Therapeutics
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Stories
- Five stocks we like better than Design Therapeutics
- Canadian Penny Stocks: Can They Make You Rich?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Why Invest in High-Yield Dividend Stocks?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is Put Option Volume?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
